Cargando…

117. Adjunctive Daptomycin in the Treatment of staphylococcus Aureus Bacteremia

BACKGROUND: Bloodstream infections (BSI) caused by methicillin-susceptible Staphylococcus aureus (MSSA) are associated with significant morbidity and mortality. The objective of our study was to determine whether daptomycin given in combination with an anti-staphylococcal beta-lactam improved outcom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Matthew P, Lawandi, Alexander, Butler-Laporte, Guillaume, De L’Etoile-Morel, Samuel, Paquette, Katryn, Lee, Todd C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777962/ http://dx.doi.org/10.1093/ofid/ofaa439.427

Ejemplares similares

Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial
por: Cheng, Matthew P., et al.
Publicado: (2018)

646. Adapting the modified Carbapenem Inactivation Method to assess for possible beta-lactamase mediated resistance in Piperacillin-Tazobactam resistant/ Ceftriaxone susceptible Escherichia. coli and Klebsiella pneumoniae
por: Lawandi, Alexander, et al.
Publicado: (2020)

Clinical Trials Increase Off-Study Drug Use: A Segmented Time-Series Analysis
por: Butler-Laporte, Guillaume, et al.
Publicado: (2020)

307. Rapid Resistance Development to Three Antistaphylococcal Therapies in Daptomycin-tolerant Staphylococcus aureus Bacteremia
por: Miller, Christopher R, et al.
Publicado: (2020)

276. Comparison of Ceftaroline in Combination with Either Vancomycin or Daptomycin for the Treatment of Methicillin-resistant Staphylococcus aureus Bacteremia
por: Welch, Stephanie N, et al.
Publicado: (2020)

Effectiveness of Daptomycin in Patients with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia Despite Vancomycin
por: Kale-Pradhan, Pramodini, et al.
Publicado: (2017)

711. Molecular Epidemiology of Daptomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia
por: Sundaram, Ayesha, et al.
Publicado: (2018)

197. Evaluation of Risk Factors and Outcomes Associated with Daptomycin-nonsusceptible Staphylococcus aureus Bacteremia
por: Hanna, Zachary W, et al.
Publicado: (2023)

1624. Real World Experience with Daptomycin (DAP) and Ceftaroline (CPT) Combination Therapy for Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia
por: Zidaru, Andrei, et al.
Publicado: (2020)

204. Clinical Outcomes with Ceftaroline Monotherapy versus Daptomycin-Ceftaroline Combination Therapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Andonie, Gabriela, et al.
Publicado: (2021)

1062. Daptomycin/Ceftaroline in Combination vs. Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Fox, Matthew, et al.
Publicado: (2018)

973. Pharmacokinetic/Pharmacodynamic Evaluation and Dose Optimization of Daptomycin in Pediatric Patients with Staphylococcus aureus Bacteremia
por: Olney, Katie B, et al.
Publicado: (2023)

LB3. Daptomycin Plus Fosfomycin vs. Daptomycin Monotherapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Multicenter, Randomized, Clinical Trial
por: Pujol, Miquel, et al.
Publicado: (2018)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant Staphylococcus aureus bacteremia after monotherapy failure
por: Hornak, Joseph Patrik, et al.
Publicado: (2019)

269. Clinical Characteristics and Outcomes of Persistent Staphylococcus aureus Bacteremia
por: Yang, Eunmi, et al.
Publicado: (2020)

Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin
por: Bamberger, David M
Publicado: (2007)

2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
por: Bouchard, Jeannette, et al.
Publicado: (2018)

850. External Validation of the Methicillin-Resistant Staphylococcus aureus Bacteremia Score
por: Boyle, Ellen, et al.
Publicado: (2020)

851. Compliance with Guidelines for Management of Staphylococcus aureus Bacteremia and its Effect on Mortality
por: Travez, Robert D, et al.
Publicado: (2020)

266. Ceftriaxone Versus Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Mohamed, Adham, et al.
Publicado: (2020)

213. Assessment of Compliance with Order Set and Bundle for Management of Staphylococcus aureus Bacteremia
por: Flynn, Ryan R, et al.
Publicado: (2021)

596. Distinct, Segregated Daptomycin-Susceptible and Daptomycin-Nonsusceptible Staphylococcus aureus Populations Associated with Tricuspid-Valve Infective Endocarditis
por: Miller, Christopher R, et al.
Publicado: (2019)

Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial
por: Pujol, Miquel, et al.
Publicado: (2020)

1817. Characteristics and Outcomes in Patients with Staphylococcus lugdunensis Bacteremia Compared with Staphylococcus aureus and Staphylococcus epidermidis Bacteremia
por: Yukawa, Satomi, et al.
Publicado: (2022)

67. Impact of a Pharmacist-Driven Collaborative Initiative on Staphylococcus aureus Bacteremia Management
por: Kufel, Wesley D, et al.
Publicado: (2020)

311. The Role of Transthoracic Echocardiography in Staphylococcus aureus Bacteremia; A Retrospective Chart Review
por: Aldred, Bruce M, et al.
Publicado: (2020)

627. Molecular Epidemiology of Daptomycin-resistant Staphylococcus aureus Causing Bloodstream Infections
por: Gudipati, Smitha, et al.
Publicado: (2019)

227. Staphylococcus aureus bacteremia: back to normal
por: Pedromingo Kus, Miguel Sebastian, et al.
Publicado: (2023)

292. Impact of the BACT/ALERT VIRTUO blood culture system in the management of Staphylococcus aureus bacteremia
por: Chavez, Miguel A, et al.
Publicado: (2020)

301. Penicillin Versus Cefazolin or Anti-staphylococcal Penicillins for Penicillin-Susceptible Staphylococcus aureus Bacteremia
por: Aldhaeefi, Mohammed, et al.
Publicado: (2020)

302. Peripheral IV catheters, a common source of healthcare-associated Staphylococcus aureus bacteremia
por: Young, Heather, et al.
Publicado: (2020)

264. Anti-platelet Therapy Significantly Reduces Inpatient Mortality in Patients with Staphylococcus aureus Bacteremia
por: Caffrey, Aisling, et al.
Publicado: (2020)

190. Outcomes of Early Ceftaroline-based Combination Therapy for Methicillin-resistant Staphylococcus aureus Bacteremia
por: Dolan, Mackenzie, et al.
Publicado: (2021)

187. Vancomycin Plus Ceftaroline Salvage Therapy for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Kufel, Wesley D, et al.
Publicado: (2021)

216. Bacterial Genotype and Clinical Outcomes in Solid Organ Transplant Recipients with Staphylococcus aureus Bacteremia
por: Eichenberger, Emily, et al.
Publicado: (2021)

613. Suppression of Daptomycin Resistance Development in Staphylococcus aureus Is a Class Effect of β-Lactams and Is Independent of Daptomycin–β Lactam Synergy
por: Miller, Christopher R, et al.
Publicado: (2019)

2452. Treatment and Outcomes of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
por: Hadid, Hind, et al.
Publicado: (2018)

1507. Pharmacodynamic Target Attainment of Daptomycin Against Staphylococcus aureus for Treatment of Pediatric Osteomyelitis
por: Stimes, Grant, et al.
Publicado: (2019)

282. Epidemiological Evaluation of Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA) Bacteremia: A Comprehensive Cancer Center’s 10-Year Experience
por: Ford, Charles R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ldbgb5g5msh476n7ilig7k15m5